Brompheniramine / Hydrocodone / Pseudoephedrine Dosage
Applies to the following strengths: 2 mg-1.7 mg-30 mg/5 mL; 2 mg-2.5 mg-15 mg/5 mL; 3 mg-2.5 mg-30 mg/5 mL; 2 mg-2.5 mg-30 mg/5 mL; 3 mg-2.5 mg-15 mg/5 mL; 6 mg-6 mg-45 mg/5 mL
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Cough and Nasal Congestion
Brompheniramine/hydrocodone/pseudoephedrine 2 mg-2.5 mg-15 mg/5 mL oral liquid:
10 mL orally every 4 to 6 hours.
Brompheniramine/hydrocodone/pseudoephedrine 3 mg-2.5 mg-15 mg/5 mL oral liquid:
5 to 10 mL orally every 4 to 6 hours not to exceed 40 mL daily.
Brompheniramine/hydrocodone/pseudoephedrine 6 mg-6 mg-45 mg/5 mL oral suspension, extended release:
5 mL orally every 12 hours not to exceed 10 mL daily.
Usual Pediatric Dose for Cough and Nasal Congestion
Brompheniramine/hydrocodone/pseudoephedrine 2 mg-2.5 mg-15 mg/5 mL oral liquid:
6 to 11 years: 5 mL orally every 4 to 6 hours.
12 years or older: 10 mL orally every 4 to 6 hours.
Brompheniramine/hydrocodone/pseudoephedrine 3 mg-2.5 mg-15 mg/5 mL oral liquid:
2 to 5 years: 2.5 mL orally every 4 to 6 hours not to exceed 10 mL daily.
6 to 11 years: 5 mL orally every 4 to 6 hours not to exceed 20 mL daily.
12 years or older: 5 to 10 mL orally every 4 to 6 hours not to exceed 40 mL daily
Brompheniramine/hydrocodone/pseudoephedrine 6 mg-6 mg-45 mg/5 mL oral suspension, extended release:
6 to 11 years: 2.5 mL orally every 12 hours not to exceed 5 mL daily.
12 years or older: 5 mL orally every 12 hours not to exceed 10 mL daily.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for all opioids intended for outpatient use. The new FDA Opioid Analgesic REMS is a designed to assist in communicating the serious risks of opioid pain medications to patients and health care professionals. It includes a medication guide and elements to assure safe use. For additional information: www.accessdata.fda.gov/scripts/cder/rems/index.cfm
- Opioid Analgesic REMS: To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, a REMS is required for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to complete a REMS-compliant education program; counsel patients and/or their caregivers, with every prescription on safe use, serious risks, storage, and disposal of these products; emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, and consider other tools to improve patient, household, and community safety.
Dialysis
Data not available
More about brompheniramine / hydrocodone / pseudoephedrine
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
